BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $365,941,529 | -16.7% | 5,375,959 | -0.1% | 1.06% | -12.6% |
| Q2 2023 | $439,208,093 | +10.0% | 5,380,474 | +0.0% | 1.22% | +1.5% |
| Q1 2023 | $399,104,511 | -12.7% | 5,379,492 | -2.5% | 1.20% | -22.0% |
| Q4 2022 | $457,419,859 | +12.9% | 5,519,062 | +286.7% | 1.54% | +17.3% |
| Q3 2022 | $405,286,000 | -19.4% | 1,427,064 | -1.7% | 1.31% | -19.0% |
| Q2 2022 | $503,105,000 | -20.9% | 1,451,376 | -1.2% | 1.62% | +3.5% |
| Q1 2022 | $636,187,000 | -17.1% | 1,469,118 | -0.9% | 1.56% | -4.1% |
| Q4 2021 | $767,191,000 | +6.0% | 1,482,953 | -0.7% | 1.63% | -0.8% |
| Q3 2021 | $723,888,000 | +7.3% | 1,493,878 | -0.3% | 1.64% | +6.2% |
| Q2 2021 | $674,490,000 | +18.1% | 1,498,001 | +0.2% | 1.54% | +9.7% |
| Q1 2021 | $571,098,000 | +20.4% | 1,495,296 | +0.1% | 1.41% | +20.0% |
| Q4 2020 | $474,264,000 | +28.0% | 1,493,510 | -0.1% | 1.17% | +3.2% |
| Q3 2020 | $370,422,000 | -7.6% | 1,495,267 | -1.5% | 1.14% | -21.6% |
| Q2 2020 | $400,986,000 | +38.5% | 1,518,483 | -0.5% | 1.45% | +2.3% |
| Q1 2020 | $289,431,000 | -14.0% | 1,526,376 | -0.5% | 1.42% | +10.4% |
| Q4 2019 | $336,635,000 | +9.3% | 1,533,574 | -2.6% | 1.28% | +1.4% |
| Q3 2019 | $308,091,000 | -5.8% | 1,574,546 | +0.4% | 1.27% | -3.4% |
| Q2 2019 | $326,979,000 | +5.0% | 1,568,320 | +0.0% | 1.31% | -0.7% |
| Q1 2019 | $311,377,000 | +40.3% | 1,568,254 | +2.2% | 1.32% | +17.5% |
| Q4 2018 | $221,971,000 | -27.9% | 1,533,798 | +1.6% | 1.12% | -12.0% |
| Q3 2018 | $308,048,000 | +37.8% | 1,509,224 | -0.1% | 1.28% | +30.6% |
| Q2 2018 | $223,469,000 | -2.7% | 1,510,434 | -0.7% | 0.98% | -7.6% |
| Q1 2018 | $229,630,000 | +16.8% | 1,520,323 | +0.2% | 1.06% | +16.7% |
| Q4 2017 | $196,524,000 | +6.9% | 1,516,975 | -0.2% | 0.91% | +3.9% |
| Q3 2017 | $183,780,000 | +4.3% | 1,520,228 | +1.4% | 0.87% | -3.1% |
| Q2 2017 | $176,243,000 | +14.5% | 1,499,942 | -0.9% | 0.90% | +10.4% |
| Q1 2017 | $153,859,000 | -6.5% | 1,513,617 | -5.4% | 0.82% | -12.1% |
| Q4 2016 | $164,537,000 | -8.2% | 1,600,092 | -2.2% | 0.93% | -2.4% |
| Q3 2016 | $179,188,000 | -3.2% | 1,636,421 | -0.4% | 0.95% | -3.6% |
| Q2 2016 | $185,193,000 | +18.1% | 1,642,221 | -1.0% | 0.98% | +18.8% |
| Q1 2016 | $156,756,000 | +16.4% | 1,658,440 | +10.8% | 0.83% | +32.9% |
| Q4 2015 | $134,727,000 | +4.1% | 1,496,971 | +6.9% | 0.62% | +6.7% |
| Q3 2015 | $129,480,000 | +25.0% | 1,400,394 | +33.1% | 0.58% | +43.7% |
| Q2 2015 | $103,584,000 | -1.9% | 1,051,931 | -0.1% | 0.41% | -0.5% |
| Q1 2015 | $105,627,000 | +8.5% | 1,053,220 | 0.0% | 0.41% | +4.9% |
| Q4 2014 | $97,318,000 | – | 1,053,220 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |